Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(15 sites)
United States
Providence Medical Foundation (site 209), Santa Rosa, California Hartford Hospital (site 210), Hartford, Connecticut The George Washington University Cancer Center (site 212), Washington D.C., District of Columbia Holy Cross Hospital (site 213), Fort Lauderdale, Florida Memorial Cancer Institute at Memorial Healthcare Systems (site 132), Pembroke Pines, Florida Englewood Hospital and Medical Center (site 202), Englewood, New Jersey Summit Medical Group (site 205), Florham Park, New Jersey Atlantic Health System, Morristown Medical Center (site 124), Morristown, New Jersey Presbyterian Kaseman Hospital (site 208), Albuquerque, New Mexico Weill Cornell Medicine, Cornell University (site 126), New York, New York Taylor Cancer Research Center (site 204), Maumee, Ohio Cancer Care Associates of York (site 206), York, Pennsylvania The University of Texas MD Anderson Cancer Center (site 127), Houston, Texas Utah Cancer Specialists (site 203), Salt Lake City, Utah Puerto Rico
PanOncology Trials, Hospital Oncologico - Puerto Rico Medical Center, Río Piedras (site 200), San Juan